Zydus Receives Final Approval From The USFDA For Oxcarbazepine Tablets USP, 150 mg, 300 mg and 600 mg

Zydus Receives Final Approval From The USFDA For Oxcarbazepine Tablets USP, 150 mg, 300 mg and 600 mg

The product will be manufactured at the group’s formulation manufacturing facility in Baddi, Himachal Pradesh (India).

FPJ Web DeskUpdated: Tuesday, July 04, 2023, 11:57 AM IST
article-image
Zydus Receives Final Approval From The USFDA For Oxcarbazepine Tablets USP, 150 mg, 300 mg and 600 mg | Image: Zydus (Representative)

Zydus Lifesciences Limited has received final approval from the United States Food and Drug Administration (USFDA) for Oxcarbazepine Tablets USP, 150 mg, 300 mg and 600 mg, the company announced through an exchange filing.

Oxcarbazepine is used alone or with other medications to treat seizure disorders (epilepsy). The product will be manufactured at the group’s formulation manufacturing facility in Baddi, Himachal Pradesh (India).

Oxcarbazepine Tablets USP, 150 mg, 300 mg and 600 mg had annual sales of USD 105 mn in the United States (IQVIA MAT May 2023).

The group now has 374 approvals and has so far filed over 442 ANDAs since the commencement of the filing process in FY 2003-04.

RECENT STORIES

Gold Slips ₹200 To ₹98,670/10g, Silver Tumbles ₹500 To ₹1,10,500/Kg

Gold Slips ₹200 To ₹98,670/10g, Silver Tumbles ₹500 To ₹1,10,500/Kg

Axis Bank Q1 FY26 Net Profit Falls 4% To ₹5,806 Crore Amid Rise In Bad Loans

Axis Bank Q1 FY26 Net Profit Falls 4% To ₹5,806 Crore Amid Rise In Bad Loans

Sensex-Nifty Decline On IT Selloff & Foreign Fund Outflows, Weak Earnings Add Pressure

Sensex-Nifty Decline On IT Selloff & Foreign Fund Outflows, Weak Earnings Add Pressure

South Indian Bank Reports 10% Rise In Q1 Net Profit To ₹322 Crore, Sees Strong Asset Quality Gains

South Indian Bank Reports 10% Rise In Q1 Net Profit To ₹322 Crore, Sees Strong Asset Quality Gains

Wipro Q1 Profit Rises 9.8% to ₹3,336.5 Cr, Marginal Revenue Growth Amid Macro Pressures

Wipro Q1 Profit Rises 9.8% to ₹3,336.5 Cr, Marginal Revenue Growth Amid Macro Pressures